Desirée Hao

A plain language summary of the SAVANNAH study: savolitinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification whose cancer had grown or spread on osimertinib

Filippo de Marinis, T H Kim, Laura Bonanno, Susanna Cheng et autres

What is this summary about?In the SAVANNAH study, patients with a type of lung cancer called advanced non-small cell lung cancer (NSCLC), which had grown or spread (known as ‘progressed’) on previous osimertinib treatment, were treated with savolitinib plus osimertinib.Patients had NSCLC …

A plain language summary of the SAVANNAH study: savolitinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification whose cancer had grown or spread on osimertinib

Filippo de Marinis, Tae Min Kim, Laura Bonanno, Susanna Cheng et autres

What is this summary about?In the SAVANNAH study, patients with a type of lung cancer called advanced non-small cell lung cancer (NSCLC), which had grown or spread (known as ‘progressed’) on previous osimertinib treatment, were treated with savolitinib plus osimertinib.Patients had NSCLC …

A plain language summary of the SAVANNAH study: savolitinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification whose cancer had grown or spread on osimertinib

Filippo de Marinis, T H Kim, Laura Bonanno, Susanna Cheng et autres

What is this summary about?In the SAVANNAH study, patients with a type of lung cancer called advanced non-small cell lung cancer (NSCLC), which had grown or spread (known as ‘progressed’) on previous osimertinib treatment, were treated with savolitinib plus osimertinib.Patients had NSCLC …

A plain language summary of the SAVANNAH study: savolitinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification whose cancer had grown or spread on osimertinib

Filippo de Marinis, Tae Min Kim, Laura Bonanno, Susanna Cheng et autres

Plain Language SummaryWhat is this summary about? In the SAVANNAH study, patients with a type of lung cancer called advanced non-small cell lung cancer (NSCLC), which had grown or spread (known as ‘progressed’) on previous osimertinib treatment, were treated with savolitinib plus …

it, kr, ca, gb, tw, us, fr, vn, in, jp, es, br, nl, sg, pl (code pays fourni par la source)

Factors Associated With Long‐Term Survivors With Epidermal Growth Factor Receptor Positive Non‐Small Cell Lung Cancer Treated With First or Second‐Generation Tyrosine Kinase Inhibitors: A Canadian Multi‐Center Cohort

Heather Halperin, Amanda J.W. Gibson, Ali Hussein, Mike Sung et autres

BACKGROUND: non-small cell lung cancer (NSCLC) populations when treated with first/second generation tyrosine kinase inhibitor (TKI). Generalizability to more heterogeneous populations is less understood. OBJECTIVE: treated with first-line TKIs. METHODS: NSCLC diagnoses receiving a first/second generation epidermal growth factor receptor-TKI between 2004 …

ca, nz (code pays fourni par la source)

Effects of serotonergic drugs on immune checkpoint inhibitor response: a pooled analysis of individual patient data from four Canadian Cancer Trials Group (CCTG) trials

Courtney H. Coschi, Keyue Ding, Dongsheng Tu, Christopher O’Callaghan et autres

Background Immune checkpoint inhibitors (ICIs) are used to treat various cancers. Serotonin receptors are expressed by immune cells. In preclinical models, serotonergic drugs affect T-cell cytokine production, proliferation and apoptosis. Interactions between clinical serotonergic drug use and dual ICI treatment remain unknown.Methods …

ca (code pays fourni par la source)

Assessing Disparities in Who Accepts an Early Palliative Care Consultation

Heather Halperin, Philip Akude, Seema King, Patricia D. Biondo et autres

Early palliative care improves quality of life for patients with life-limiting illnesses, but access is often inequitable. The goal of this study was to assess disparities in early specialist palliative care (SPC) consultation among newly diagnosed stage IV lung cancer patients. All …

ca (code pays fourni par la source)

Effects of cannabinoids on immune checkpoint inhibitor response: CCTG pooled analysis of individual patient data

Courtney H. Coschi, Keyue Ding, Justin Tong, Dongsheng Tu et autres

Background Immune checkpoint inhibitors (ICIs) benefit patients across various tumor types. ICIs block cancer and T-cell interactions whereas cannabinoids may inhibit T-cell activation, reducing lysis of tumor cells. Interactions between cannabinoid use and dual ICI treatment remain unknown.Methods Individual patient data from …

ca, us (code pays fourni par la source)

Abstracts of the 2024 Canadian Association of Medical Oncologists Annual Scientific Meeting

Alexi Campbell, Sharlene Gill, Desirée Hao, Suneil Kumar Khanna et autres

On behalf of the Canadian Association of Medical Oncologists, we are pleased to present the abstracts of the 2024 Annual Scientific Meeting. The CAMO Annual Scientific Meeting (ASM) took place from 24-26 October 2024 in an in-person event in Ottawa, ON. Twenty-four …

ca (code pays fourni par la source)

Patient-Rated Acceptability of Automatic Palliative Care Referral: A Prospective Cohort Study

Seema King, Aynharan Sinnarajah, Sadia Ahmed, Alessandra Paolucci et autres

CONTEXT: Timely palliative care can alleviate distress after diagnosis of an incurable cancer. However, late referrals to palliative care continue, reflecting various provider and patient barriers. OBJECTIVES: To determine patient/caregiver-reported acceptability of a phone call offering a supportive and palliative care (SPC) …

ca (code pays fourni par la source)

Workforce Trends Among Canadian Medical Oncologists and Medical Oncology Trainees over Two Decades

Adam Michael Fundytus, Sarah Cook, Steven Yip, Shaun K. Loewen et autres

Background: Understanding oncology health human resources across Canada is critical to the delivery of quality cancer care. Little has been published about the medical oncology (MO) workforce and trainees; this study sought to characterize trends in the MO workforce and explore the …

ca (code pays fourni par la source)

A Canadian Perspective on Systemic Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma

Anna Spreafico, Eric Winquist, Cheryl Ho, Brian P. O'Sullivan et autres

Although the majority of patients with nasopharyngeal carcinoma (NPC) present with early-stage or locoregional disease that can be treated with definitive radiotherapy, approximately 20% of patients experience disease recurrence, and 15% present with metastatic disease that is not amenable to curative therapy. …

ca (code pays fourni par la source)